ELI LILLY & Co
LLYPharma & biotechlilly.com
Latest available resultsSeptember 30, 2026Quarter · 10-Q filed Oct 29, 2026
Next reportFebruary 2, 2027pre-market · forecast 11.163 $/share
Revenue
$24.40B
▲ +38.6% vs prior year YoY
Net income
$6.45B
▲ +15.5% vs prior year YoY
EPS
7.22$
▲ +16.3% vs prior year YoY
Net margin
26.4%
▼ -5.3 pp vs prior year YoY
Revenue▲ +38.6%
Margins (% of revenue)GrossOperating N/ANet
Net income▲ +15.5%
EPS▲ +16.3%
Financial statements
View 10-Q filed October 29, 2026 on SEC ↗| Metric | Dec 2024* | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025* | Mar 2026 | Jun 2026 | Sep 2026 | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $13.53B | $12.73B | $15.56B | $17.60B | $19.29B | $19.80B | $22.97B | $24.40B | ▲ +38.6% |
| Gross profit | $11.13B | $10.50B | $13.11B | $14.59B | $15.92B | $16.22B | $19.71B | $20.46B | ▲ +40.2% |
| Operating incomenever filed | — | — | — | — | — | — | — | — | — |
| Net income | $4.41B | $2.76B | $5.66B | $5.58B | $6.64B | $7.40B | $7.09B | $6.45B | ▲ +15.5% |
| R&D | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | — | 3.06 $ | 6.29 $ | 6.21 $ | — | 8.26 $ | 7.94 $ | 7.22 $ | ▲ +16.3% |
| Margins (% of revenue) | |||||||||
| Gross | 82.2 % | 82.5 % | 84.3 % | 82.9 % | 82.5 % | 81.9 % | 85.8 % | 83.9 % | ▲ +1.0 pt |
| Operating | — | — | — | — | — | — | — | — | — |
| Net | 32.6 % | 21.7 % | 36.4 % | 31.7 % | 34.4 % | 37.4 % | 30.9 % | 26.4 % | ▼ -5.3 pt |
| Balance sheet | |||||||||
| Assets | $78.72B | $89.39B | $100.92B | $114.94B | $112.48B | $116.58B | $142.28B | $148.07B | ▲ +28.8% |
| Liabilities | $64.44B | $73.54B | $82.57B | $91.08B | $85.94B | $85.38B | $108.40B | $107.80B | ▲ +18.4% |
| Equity | $14.27B | $15.85B | $18.35B | $23.85B | $26.54B | $31.20B | $33.88B | $40.27B | ▲ +68.8% |
| Cash | $3.27B | $3.09B | $3.38B | $9.79B | $7.27B | $5.28B | $8.95B | $4.88B | ▼ -50.1% |
| Capital | |||||||||
| Shares outstanding | 948.17M | 947.74M | 946.46M | 945.38M | 943.36M | 941.74M | 941.36M | 940.75M | ▼ -0.5% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.